Ondameton (Ondansetron)

Ondansetron, the active ingredient in Ondameton, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients. GNH USA supplies Ondameton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Ondameton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ondameton is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways.

- Chemotherapy‑induced nausea and vomiting: Helps reduce the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: Decreases the incidence of nausea during and after radiotherapy. - Post‑operative nausea and vomiting: Lowers the risk of vomiting after surgical procedures. - Hyper‑emesis gravidarum: Provides symptomatic relief in severe pregnancy‑related nausea. - Nausea due to other causes: Improves      

The              …  … … ...

    …  … … ...  g